18F-FLT PET/CT在疑似复发或残留淋巴瘤中的先导试验最终结果
该先导性前瞻性试验纳入52例末次治疗或随访时FDG PET/CT阳性或可疑的成人淋巴瘤患者,加做18F-FLT PET/CT。结果显示两种示踪剂在65%患者中再分期一致,FLT-SUVmax区分良恶性略优于FDG,但与Ki-67无显著相关。结论认为FLT并不显著优于FDG,不太可能独立应用,或仅作为FDG的补充用于少数特定情况。
要点
- 疑似复发或残留淋巴瘤中,FDG与FLT再分期一致率为65%。
- FLT-SUVmax区分良恶性略优于FDG,但FLT并不显著优于FDG。
- FLT两种指标与Ki-67均无统计学显著相关。
核心结论
- 在复发或残留淋巴瘤临床情境中,FLT并不显著优于FDG,不太可能独立应用。
- FLT或可限于少数特定病例,作为标准FDG显像的补充以确认诊断或确定更好的活检靶点。
- 由于FLT表现欠佳,许多发现仍无法定论,需进一步诊断操作并降低加做FLT扫描的有效性。
研究设计与样本
- 前瞻性先导性试验,纳入52例成人淋巴瘤患者。
- 入组条件为末次治疗或随访时FDG PET/CT阳性或可疑,加做18F-FLT PET/CT。
- 记录最摄取病灶的SUVmax和肿瘤-本底比(TBR)。
- 以活检或(不可及时)临床或影像评估作为参考标准。
主要发现
- 52例中20例(38%)有组织学结果,其中14例有增殖指数Ki-67。
- 13/52例(25%)排除疾病,包括1例反应性滤泡增生、5例反应性炎症组织、4例反应性淋巴结、2例结节样肉芽肿及1例非特异性盲肠周围发现。
- FDG与FLT再分期一致34/52例(65%),不一致18/52例(35%)。
- 疾病组FDG的SUVmax和TBR均显著高于无病组(p=0.0231和0.0219),FLT的SUVmax和TBR亦显著更高(p=0.0008和0.0016)。
- FLT-SUVmax区分良恶性略优于FDG(ROC-AUC:FLT-SUVmax 0.8116、TBR 0.7949;FDG-SUVmax 0.7120、TBR 0.7140)。
关键数值与推荐
- FLT-SUVmax界值3对应95%敏感性、81%准确性和39%特异性。
- FLT-SUVmax界值7对应100%敏感性、41%准确性和56%特异性。
临床怎么用
- 在疑似复发或残留淋巴瘤中,FLT PET/CT不宜替代FDG PET/CT。
- FLT或可作为FDG的补充,用于少数需确认诊断或优化活检靶点的病例。
局限性
- FLT表现欠佳,许多发现仍无法定论,需进一步诊断操作。
- 加做FLT扫描的有效性因此降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the role of F-18-Fluorothymidine (FLT) PET/CT in lymphoma patients with suspected recurrent or residual disease. METHODS: Adult lymphoma patients presenting with positive or equivocal F-18-FDG PET/CT at end-treatment or follow-up were prospectively addressed to an additional F-18-FLT-PET/CT. SUV max and tumour-to-background ratios (TBRs) were recorded for the most avid lesion. Biopsy or, when not available, clinical or imaging assessment were employed as standard of reference. RESULTS: Overall 52 patients were recruited. Histology was available in 20/52 patients (38%), proliferation-index (Ki-67) in 14/20. Disease was excluded in 13/52 patients (25%) (one reactive follicular hyperplasia, five reactive-inflammatory tissues, four reactive nodes, two nodal sarcoid-like and one non-specific peri-caecal finding). FDG and FLT scans were concordant in disease restaging in 34/52 patients (65%), whereas in 18/52 cases (35%) relevant discrepancies were recorded. SUV max and TBR were significantly higher in the disease versus the disease-free group, with both tracers (p = 0.0231 and 0.0219 for FDG; p = 0.0008 and 0.0016 for FLT). FLT-SUVmax demonstrated slightly better performance in discriminating benign from malignant lesions (ROC-AUC: 0.8116 and 0.7949 for FLT-SUV max and TBR; 0.7120 and 0.7140 for FDG). Optimal FLT-SUV max cut-offs were searched: three would lead to 95% sensitivity, 81% accuracy, and 39% specificity, whereas seven led to 100%, 41%, and 56% respectively. No statistically significant correlation was observed between the two FLT indices and Ki-67. CONCLUSIONS: According to our results in a clinical setting of recurrent or residual lymphoma, FLT is not significantly superior to FDG and it is unlikely that it will be employed independently. FLT may be restricted to a few specific cases, as complementary to standard FDG imaging, to confirm a diagnosis or to define a better target to biopsy. However, due to FLT suboptimal performance, many findings would remain inconclusive, requiring further diagnostic procedures and reducing the effectiveness of performing an additional FLT scan.
引用
- Zanoni L, Broccoli A, Lambertini A, et al. Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. Eur J Nucl Med Mol Imaging. 2019. PMID: 31102000. doi:10.1007/s00259-019-04323-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。